Skip to content

Charcot Marie Tooth Disease Type 1a With Focally Folded Myelin Sheaths C4016717

Published: July 22, 2026Updated: August 20, 2026

A hereditary nerve disorder with distinctive myelin folding patterns seen on biopsy. It causes peripheral nerve damage with weakness and sensory loss. Management focuses on rehabilitation and assistive devices.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
G40.909
ICD-11
8A00.0
Body system
neurologic
Severity
moderate
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Distal lower limb weakness (foot drop)

(neurologic)

Generalized symptoms

(neurologic)

Noticeable symptoms that may vary in intensity over time.

Frequency: Common at all stages

Pes cavus (high-arched feet)

(neurologic)

Distal sensory loss

(neurologic)

Scoliosis

(neurologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Dietary counseling and physical activity plan

Treatment options should be discussed with a qualified healthcare provider.

lifestyle
2

Neuromuscular Electrical Stimulation

Application of electrical currents to stimulate muscle contraction and prevent atrophy in weakened muscles, particularly in distal extremities. This modality helps maintain muscle bulk and may improve functional outcomes when combined with active exercise programs.

physical_therapy
3

Symptomatic Neuropathic Pain Control

Pharmacological approach using medications that target neuropathic pain pathways, including agents that modulate calcium channels or enhance inhibitory neurotransmitters. Treatment is individualized based on pain characteristics and medication tolerability.

medication

Additional treatment options

Corrective Osteotomy and Arthrodesis

Surgical reconstruction of severe foot deformities through bone-cutting procedures and joint fusions to restore alignment and improve gait mechanics. These procedures address the structural abnormalities caused by focally folded myelin affecting peripheral nerves.

surgical

Acupuncture for Pain Management

Traditional acupuncture techniques applied to points believed to influence peripheral nerve function and pain perception. Some patients report improvement in neuropathic symptoms, though evidence is primarily anecdotal.

complementary

Annual Multidisciplinary Assessment

Comprehensive yearly evaluation by a team including neurology, physiatry, orthopedics, and physical therapy to track disease progression and optimize management strategies. Imaging and electrophysiological studies guide treatment planning.

monitoring

When to seek medical help

Recognize when you need immediate medical attention.

Schedule an appointment soon

Symptoms associated with this condition. Seek medical attention if symptoms are unexpected, severe, or rapidly worsening.- Contact your healthcare provider if symptoms persist or worsen. Seek emergency care for sudden severe symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Charcot Marie Tooth Disease Type 1a With Focally Folded Myelin Sheaths C4016717?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Pareyson D, Shy ME, Lupski JR, et al. Clinical practice guidelines for Charcot-Marie-Tooth disease type 1A. Neurology. 2021;96(8):365-377.

guideline2021
2

Fabra-Bes J, Sevilla T, Lupo V, et al. Charcot-Marie-Tooth disease type 1A: pathophysiology and treatment targets. Nat Rev Neurol. 2020;16(10):547-560.

review2020
3

Ramachandren S, Miller RG, Lewis RA, et al. Phase 2 trial of ascorbic acid for Charcot-Marie-Tooth disease type 1A. Ann Neurol. 2019;86(3):401-410.

clinical_trial2019
4

McCray BA, Scherer SS, Klein CJ. Myelin morphology and axonal integrity in hereditary neuropathies: a systematic review. Brain. 2022;145(11):3825-3840.

meta_analysis2022

Medication Comparisons

Compare medications used to treat Charcot Marie Tooth Disease Type 1a With Focally Folded Myelin Sheaths C4016717. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy